Supporting Information

Similar documents
NK cell flow cytometric assay In vivo DC viability and migration assay

D CD8 T cell number (x10 6 )

Blocking antibodies and peptides. Rat anti-mouse PD-1 (29F.1A12, rat IgG2a, k), PD-

Supplementary Figure 1. Characterization of basophils after reconstitution of SCID mice

Supporting Information

SUPPLEMENTARY INFORMATION

Cytotoxicity LDH Assay Kit-WST

SUPPLEMENTARY INFORMATION

Supporting Information

Supporting Information

Detailed step-by-step operating procedures for NK cell and CTL degranulation assays

Supplementary Figure 1. Efficient DC depletion in CD11c.DOG transgenic mice

MATERIALS AND METHODS. Neutralizing antibodies specific to mouse Dll1, Dll4, J1 and J2 were prepared as described. 1,2 All

SUPPORTING INFORMATIONS

Long-term consumption of Carnosine contributes to improving effector functions of NK cells

W/T Itgam -/- F4/80 CD115. F4/80 hi CD115 + F4/80 + CD115 +

Figure S1. Gating strategy used in NK cells and γδ T lymphocytes coculture An example of flow cytometry analysis shows the gating of NK cells and γδ

Supporting Online Material for

Supplementary Figures

SUPPLEMENT Supplementary Figure 1: (A) (B)

Supplemental Materials for. Effects of sphingosine-1-phosphate receptor 1 phosphorylation in response to. FTY720 during neuroinflammation

BMDCs were generated in vitro from bone marrow cells cultured in 10 % RPMI supplemented

Supplemental Information. CD4 + CD25 + Foxp3 + Regulatory T Cells Promote. Th17 Cells In Vitro and Enhance Host Resistance

CD14 + S100A9 + Monocytic Myeloid-Derived Suppressor Cells and Their Clinical Relevance in Non-Small Cell Lung Cancer

Supplemental Figure 1

Electron micrograph of phosphotungstanic acid-stained exosomes derived from murine

Supplemental Figure 1. Cell-bound Cetuximab reduces EGFR staining intensity. Blood

SUPPLEMENTARY INFORMATION

SUPPLEMENTARY INFORMATION

B6/COLODR/SPL/11C/83/LAP/#2.006 B6/COLODR/SPL/11C/86/LAP/#2.016 CD11C B6/COLODR/SPL/11C/80/LAP/#2.011 CD11C

Supplementary Materials for

Supplementary Figure S1. PTPN2 levels are not altered in proliferating CD8+ T cells. Lymph node (LN) CD8+ T cells from C57BL/6 mice were stained with

Supplementary Figure S1. Flow cytometric analysis of the expression of Thy1 in NH cells. Flow cytometric analysis of the expression of T1/ST2 and

NKTR-255: Accessing The Immunotherapeutic Potential Of IL-15 for NK Cell Therapies

Supplementary Figure 1 Protease allergens induce IgE and IgG1 production. (a-c)

Supplemental Information. T Cells Enhance Autoimmunity by Restraining Regulatory T Cell Responses via an Interleukin-23-Dependent Mechanism

CD4 + T cells recovered in Rag2 / recipient ( 10 5 ) Heart Lung Pancreas

7-AAD/CFSE Cell-Mediated Cytotoxicity Assay Kit

Supplemental Figure 1. Activated splenocytes upregulate Serpina3g and Serpina3f expression.

Supplementary Fig. 1 p38 MAPK negatively regulates DC differentiation. (a) Western blot analysis of p38 isoform expression in BM cells, immature DCs

Cell isolation. Spleen and lymph nodes (axillary, inguinal) were removed from mice

ndln NK Cells (x10 3 ) Days post-infection (A/PR/8) *** *** *** Liver NK Cells (x10 4 ) Days post-infection (MCMV)

B-cell expansion and lymphomagenesis induced by chronic CD40-signaling is

Therapeutic PD L1 and LAG 3 blockade rapidly clears established blood stage Plasmodium infection

Hua Tang, Weiping Cao, Sudhir Pai Kasturi, Rajesh Ravindran, Helder I Nakaya, Kousik

a surface permeabilized

Supplementary Figure 1

Cytokine Complex Expanded Natural Killer Cells Improve Allogeneic Lung. Transplant Function via Depletion of Donor Dendritic Cells

Eosinophils are required. for the maintenance of plasma cells in the bone marrow

Supplemental Table I.

Supporting Information

Supplemental Data Figure S1 Effect of TS2/4 and R6.5 antibodies on the kinetics of CD16.NK-92-mediated specific lysis of SKBR-3 target cells.

Supplementary Data Table of Contents:

Supplemental Table 1. Primer sequences for transcript analysis

Supplementary Figure 1. IL-12 serum levels and frequency of subsets in FL patients. (A) IL-12

Intracellular MHC class II molecules promote TLR-triggered innate. immune responses by maintaining Btk activation

Supplementary Figures

Supplementary Information. Tissue-wide immunity against Leishmania. through collective production of nitric oxide

Spleen. mlns. E Spleen 4.1. mlns. Spleen. mlns. Mock 17. Mock CD8 HIV-1 CD38 HLA-DR. Ki67. Spleen. Spleen. mlns. Cheng et al. Fig.

Ex vivo Human Antigen-specific T Cell Proliferation and Degranulation Willemijn Hobo 1, Wieger Norde 1 and Harry Dolstra 2*

NKTR-255: Accessing IL-15 Therapeutic Potential through Robust and Sustained Engagement of Innate and Adaptive Immunity

L1 on PyMT tumor cells but Py117 cells are more responsive to IFN-γ. (A) Flow

Supporting Information Table of Contents

Supplementary Figure 1. H-PGDS deficiency does not affect GI tract functions and anaphylactic reaction. (a) Representative pictures of H&E-stained

Cover Page. The handle holds various files of this Leiden University dissertation.

Supplemental Figure Legends

ILC1 and ILC3 isolation and culture Following cell sorting, we confirmed that the recovered cells belonged to the ILC1, ILC2 and

Supplementary Figure 1. BMS enhances human T cell activation in vitro in a

Supplemental Methods. CD107a assay

PBMC from each patient were suspended in AIM V medium (Invitrogen) with 5% human

Supplementary Figures

Supplementary Figure 1. mrna expression of chitinase and chitinase-like protein in splenic immune cells. Each splenic immune cell population was

Supplemental Figure 1. Signature gene expression in in vitro differentiated Th0, Th1, Th2, Th17 and Treg cells. (A) Naïve CD4 + T cells were cultured

Human Immunodeficiency Virus Type-1 Myeloid Derived Suppressor Cells Inhibit Cytomegalovirus Inflammation through Interleukin-27 and B7-H4

SUPPLEMENTARY INFORMATION

and follicular helper T cells is Egr2-dependent. (a) Diagrammatic representation of the

Figure S1. Generation of inducible PTEN deficient mice and the BMMCs (A) B6.129 Pten loxp/loxp mice were mated with B6.

% of live splenocytes. STAT5 deletion. (open shapes) % ROSA + % floxed

Supporting Information

a 10 4 Link et al. Supplementary Figure 1 Nature Immunology: doi: /ni.1842 Cells per mouse ( 10 5 ) TRPV2KO anti-gr1 anti-gr anti-f4/80

SDC (Supplemental Digital Content) Figure S1. Percentages of Granzyme B expressing CD8 + T lymphocytes

Supplementary Figure 1. Deletion of Smad3 prevents B16F10 melanoma invasion and metastasis in a mouse s.c. tumor model.

L-selectin Is Essential for Delivery of Activated CD8 + T Cells to Virus-Infected Organs for Protective Immunity

LAB 1, Immunology. Laboratory manual Immunology and Infection Biology Biomedicine course Autumn 2007

Supplementary data Supplementary Figure 1 Supplementary Figure 2

Defective STAT1 activation associated with impaired IFN-g production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2

SUPPLEMENTARY FIGURE 1

T H 1, T H 2 and T H 17 polarization of naïve CD4 + mouse T cells

Effector memory T helper cells secrete IFN-γ upon stimulation with cytokines: a role in chronic inflammation

pro-b large pre-b small pre-b CCCP (µm) Rag1 -/- ;33.C9HCki

In vitro human regulatory T cell suppression assay

Aquaporin-9-expressing neutrophils are required for the establishment of contact hypersensitivity

Supplementary Figure 1.

Optimization of a LanthaScreen Kinase assay for JAK1

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

Supporting Information

Supplemental Information. Checkpoint Blockade Immunotherapy. Induces Dynamic Changes. in PD-1 CD8 + Tumor-Infiltrating T Cells

Supplementary information. Characterization of c-maf + Foxp3 - Regulatory T Cells Induced by. Repeated Stimulation of Antigen-Presenting B Cells

Supplemental Information. Gut Microbiota Promotes Hematopoiesis to Control Bacterial Infection. Cell Host & Microbe, Volume 15

Cytotoxicity assays. Rory D. de Vries, PhD 1. Viroscience lab, Erasmus MC, Rotterdam, the Netherlands

Transcription:

Supporting Information lpek et al. 1.173/pnas.1121217 SI Materials and Methods Mice. cell knockout, inos / (Taconic arms), Rag1 /, INγR /, and IL-12p4 / mice (The Jackson Laboratory) were maintained and/or bred under barrier conditions in the ana- arber ancer Institute nimal acility in accordance with institutional and National Institutes of Health guidelines. ell Preparation and ytofluorimetry. Single-cell suspensions were prepared from spleen, skin lymph nodes, lungs, and liver by mechanical disruption. one marrow cells were isolated by flushing media through tibias and femurs. or myeloid cell analysis, spleens were disrupted by forceps teasing and incubated in digestion buffer containing RPMI (Invitrogen),.2 mg/ml collagenase P (Roche),.1 mg/ml Nase I (Sigma), and. mg/ml dispase (Invitrogen) for 4 min at 37. fter R lysis with K solution, cells were suspended in S buffer containing cr-block antibody (2.4G2) and stained with fluorescently labeled monoclonal antibodies (mbs) specific for NK1.1 (PK136), 3ε (14-211), 49b (X), 4 (3-11), 4.1 (2), 44 (1M7), α (3-6.7), 122 (TM-1), 244.2 (24), NKG2 (7), 11b (M1/7), 27 (LG.31), Ly49H (31), NKp46 (R&), 43 (111), 11c (HL3), 22 (R3-62), 69 (1H.23), P1 (J43), KLRG1 (21), NKG2 (16a11), 4 (m4.7), NM1 (1), Ly49 (4), Ly-49HI///H (1411), Gr1 (R6-), γ-chain/132 (TUGm2), and 3ζ (61.2) or isotype controls. or intracellular staining, splenocytes were plated in 24-well plates at 2 1 6 cells/ml in RPMI supplemented with % S and activated with PM ( ng/ml) and ionomycin ( ng/ml) for h, on anti-nk1.1 (PK136; 2 μg/ml) or isotype antibody (2 μg/ml)- coated plates for h with monensin (GolgiStop, iosciences) for the last 4 h, or on anti-3ε ( μg/ml) and anti-2 (2 μg/ ml)-coated plates for 24 h with monensin for the last 1 h. In some experiments, 4 1 6 4.1 + OT-1 splenocytes were transferred i.v. followed by IL-/IL-Rα complex treatment. Splenocytes were stimulated h with SIINKL peptide (2 μg/ml, naspec). fter cell-surface staining with anti-nk1.1, -3ε, -α, 4, or 4.1, cells were fixed and intracellularly stained using ytoix/ytoperm reagents ( iosciences) containing anti-inγ, TNα, or isotype control. egranulation was analyzed using similar conditions in the presence of anti-17a-p or isotype control. Proliferative potential was tested by intracellular staining using anti-k i -67 ( iosciences) or isotype control. LI assay was performed according to manufacturer s protocol (Immunohemistry Technologies). ells were analyzed using S alibur, S ria ( iosciences) and lowjo software (Tree Star). Modifications to IL-/IL-Rα Treatments. Leukocytes were depleted using mbs specific for α (2.43, 2 μg) and 4 (GK1., 3 μg) (ioxell). ntibodies were injected every 3 d intraperitoneally starting 2 d before IL-/IL-Rα complex treatment until the end of the sustained treatments. Leukocyte depletion was verified by cytofluorimetry. TLR3 ligand PolyI: (G Healthcare) was injected intraperitoneally (1 μg in 1 μl of PS per mouse) with the last dose of IL-/IL-Rα complexes during sustained treatments. NK ell ytotoxicity ssays. In vitro cytotoxicity assays were performed by lactate dehydrogenase release (LH) assay (ytotox 96 nonradioactive cytotoxicity assay, Promega) according to manufacturer s protocol. NK cells were enriched in splenocytes by depletion of 3ε + and 19 + cells using biotinylated antibodies and MS (Miltenyi). Proportion of NK cells were determined in each sample by flow cytometry and normalized among three groups to have 2 3% NK cells in each effector population. ssay was performed in 96-well U-bottom plates with 1 1 4 Y1 cells with different amounts of NK cell-enriched splenocytes to obtain effector:target ratios indicated. bsorbance was recorded at 49 nm using a Victor 3V plate reader (Perkin-lmer). Percentage of cytotoxicity was calculated as [(xperimental-ffector spontaneous Target spontaneous)/target maximum Target spontaneous) 1]. or in vivo killing, NK cell cytotoxicity against allogeneic target cells was assessed by a carboxyfluorescein succinimidyl ester (S)-based in vivo assay. riefly, syngeneic splenocytes (H-2b) labeled with.2 μm S (S low ) served as the control population, and allogeneic splenocytes (H-2q) labeled with. μm S (S high ) served as the target population. S low and S high cells at a 1:1 ratio (total of 3 1 6 cells) were injected i.v. into control mice or IL-/IL-Rα complex-treated mice 2 d after the last dose. The ratio of S low and S high cells in spleen was determined using cytofluorometry 3 h later relative to the ratio in NK1.1-depleted control mice. epletion was verified using anti- 49b staining. Percentage of specific killing was calculated as: [(1 (Ratio sample /Ratio NK1.1 depleted )) 1]. T ell Suppression ssay. Myeloid cells from spleens of mice that received sustained treatment were enriched by depletion of NK1.1 +, 3ε +, 19 + cells using biotinylated antibodies and MS. S-labeled OTIxrag1 / cells (1 1 per well) were cultured alone or in 1:1 ratio with myeloid cells in the presence or absence of SIINKL peptide (1 ng/ml) for 3 d. + cells were analyzed for S dilution by flow cytometry. lpek et al. www.pnas.org/cgi/content/short/1121217 1of

treatment nalysis 2 d 2 d 3 d 3 d 2 d Transient treatment #Splenocytes (x1 6 ) 4 3 2 1 NK1.1 1 4 1 4 2.1 3.4 1.1 1 3 1 3 1 3 1 2 1 2 1 2 1 1 1 1 1 1 1 1 1 1 11 12 13 14 1 2 3 4 1 1 1 1 1 1 11 12 13 14 3ε 1 4 2 6 1 4 2 #NK cells (x1 6 ) 1. 2.. 4 Lymph nodes #NK cells (x1 4 ) 24 16 one marrow 4 2 in 4 + gate 24 16 Liver in 4+ gate 4 3 2 1 Lung ig. S1. nalysis of NK cell expansion upon in vivo stimulation with IL-/IL-Rα complexes. () typical treatment protocol used throughout the study. In sustained treatments, mice received five doses of IL-/IL-Rα complexes every 2 3 d intraperitoneally. In transient treatments, mice received a single dose at the same time as the fifth dose of sustained treatment. Two days later, lymphocytes were analyzed by phenotyping, intracellular cytokine staining, degranulation, and in vivo killing assays. () Total splenocyte numbers in untreated (n = 12) mice or upon transient (n = 12) and sustained (n = 16) treatments. ach circle represents an individual mouse. Lines indicate the average value. () Representative dot plots showing expansion of NK1.1 + 3ε (NK) cells in the spleens analyzed by flow cytometry. Numbers indicate percentage of cells in the gates. () Increase in percentage (Left) and number (Right) of splenic NK cells in untreated (n = 12) mice or upon transient (n = 12) and sustained (n = 16) treatments. ach circle represents an individual mouse. Lines indicate the average value. () Percentage and number of NK cells in lymph nodes, percentage of NK cells in bone marrow, and percentage of NK cells within 4 + cells in liver and lungs of untreated (Un) mice or upon transient (Tr) and sustained (Su) treatments (n = 3). Significance: P <., P <.1, P <.1; NS, not significant. ata are means ± S. Spleen one marrow 1 6 4 2 1 6 4 2 1 6 4 2 1 6 4 2 Transient Transient 11b + 27-11b + 27 + 11b - 27 + 11b - 27-11b + KLRG1 + 11b + KRLG1-11b - KLRG1 + 11b - KRLG1 - ig. S2. ccumulation of mature NK cells upon sustained in vivo stimulation with IL-/IL-Rα complexes. ar graphs showing frequency of NK cells in different developmental stages based on 11b and 27 expression (Upper) and 11b and KLRG1 expression (Lower) inspleen() and bone marrow () of untreated mice or upon transient and sustained treatments (n = 6). Statistics only shown for white bars indicating the mature NK population. Significance: P <., P <.1, P <.1. lpek et al. www.pnas.org/cgi/content/short/1121217 2of

2 4 6 1 2 4 6 1 %INγ + NK cells 1 6 4 2 Transient 3 2 1 Lymph nodes one marrow Liver Transient anti-nk1.1 stimulation 3 7 6 2 4 3 1 2 1 %INγ+ NK cells KLRG1 - KLRG1 + %17a + 1 6 4 2 NK1.1 depletion control 4 62.3 37.7 77.1 22.9 6 44 1 1 1 2 1 3 1 4 1 1 1 1 2 1 3 1 4 1 1 1 1 2 1 3 1 4 1 1 1 1 2 1 3 14 S 49b 1 4 1 3 1 2 1 1 1 ontrol NK1.1-depleted 3.3 S 1 4 1 3 1 2 1 1 1 G 1 + PolyI: ig. S3. Impaired effector function of NK cells upon sustained in vivo stimulation with IL-/IL-Rα complexes. () Percentage of splenic INγ + NK cells upon PM/ionomycin stimulation shown (n = 11). () MI of INγ + NK cells upon PM/ionomycin stimulation shown for lymph nodes (n = ), bone marrow (n = 3), and liver (n = 3). White bars, untreated; gray bars, transient; black bars, sustained treatment. () INγ production by KLRG1 (white) and KLRG1 + (black) NK cells in spleen of untreated mice or upon transient and sustained treatments (n = 3). (Left) MI of INγ upon PM/ionomycin stimulation. (Right) Percentage of INγ + NK cells upon anti-nk1.1 stimulation. () egranulation of PM/ionomycin stimulated NK cells from untreated mice or upon transient and sustained treatments (n = ). () Representative histograms showing S + cells in the spleens of mice analyzed for in vivo cytotoxicity assays. Numbers indicate percentage of S low and S high cells. () epletion of NK1.1 + cells using anti-nk1.1 (PK136) antibody for in vivo killing assays. Representative dot plots showing NK cell depletion by 49b staining versus forward scatter (S) in spleen. Numbers indicate percentage. (G) ffect of PolyI: treatment on INγ production by NK cells. MI of INγ + NK cells shown (n = 3). PolyI: was injected during the last dose of sustained treatments. Significance: P <., P <.1, P <.1; NS, not significant. ata are means ± S. 6 4 2 ontrol depleted 6 4 2 ontrol 4 depleted 3 2 1 Wild-type cell 2 1 Rag1 #11b + cells (x1 6 ) 4 3 2 1 Gr1 low Gr1 high unstimulated OTI OTI+Myeloid.61 96 1 11 12 13 14 1 11 12 13 14 1 11 12 13 14 S 2 1 INγR 6 4 2 inos 16 12 4 IL-12p4 G %122 + 1 6 4 2 %γ-chain + 1 6 4 2 γ-chain MI 6 4 2 H 4 3 2 1 3ζ-chain MI ig. S4. ffect of different immune cells and immunomodulatory molecules on NK cell function sustained in vivo stimulation with IL-/IL-Rα complexes. () ffect of (Left) and 4 (Right) T cell depletion on NK cell function upon sustained in vivo stimulation with IL-/IL-Rα complexes. MI of INγ + NK cells upon PM/ionomycin stimulation shown (n = 3). () ffect of cells on NK cell function assessed in wild-type () or cell-knockout () mice upon sustained in vivo stimulation with IL-/IL-Rα complexes. MI of INγ + NK cells upon PM/ionomycin stimulation shown (n = 3). () MI of INγ + NK cells in IL-/IL-Rα treated or untreated Rag1 mice upon PM/ionomycin stimulation (n = 3). () Number of 11b + Gr1 low (white bars) or Gr1 high (black bars) cells in spleens upon IL-/IL- Rα treatments (n = 9). () Representative histograms showing OV-specific OTI T cell proliferation in the presence of SIINKL peptide and myeloid cells enriched from spleens of mice that received sustained in vivo stimulation with IL-/IL-Rα complexes. Numbers indicate percentage of divided cells. () ffect of INγ (Left), inos (enter) and IL-12p4 (Right) on NK cell function upon sustained in vivo stimulation with IL-/IL-Rα complexes. MI of INγ + NK cells upon PM/ ionomycin stimulation shown (n = 3). (G) ar graphs show percentage of 122 + (Left) and common γ-chain + (enter) NK cells, and MI of common γ-chain + NK cells (Right) (n =3 ). (H) MI of 3ζ-chain + NK cells (n = 3). Significance: P <., P <.1; NS, not significant. ata are means ± S. lpek et al. www.pnas.org/cgi/content/short/1121217 3of

% T cells 6 4 2 16 12 4 # T cells (x1 6 ) 44 23..3 92.2 1 11 12 13 14 1 11 12 13 14 1 11 12 13 14 %44hi 1 6 4 2 Transient 69 6.9 31.. P1 3.6 12 1.7 KLRG1 1 11 12 13 14 1 11 12 13 14 1 11 12 13 14 1 3. 1 11 12 13 14 1 11 12 13 14 1 11 12 13 14 1.1 1 11 12 13 14 1 11 12 13 14 1 11 12 13 14 %69+ %P1+ %KLRG1 + 4 3 2 1 2 1 2 1 %INγ + T cells %17a+ T cells 1 6 4 2 1 6 4 2 Transient anti-3ε/2 stimulation INγ + INγ - %INγ+ OTI cells 4 3 2 1 1 6 4 2 Peptide stimulation ig. S. xpansion and activation of T cells upon in vivo stimulation with IL-/IL-Rα complexes. () Increase in percentage (Left) and number (Right) of splenic T cells in untreated (n = 12) mice or upon transient (n = 12) and sustained (n = 16) in vivo stimulation with IL-/IL-Rα complexes. ach circle represents an individual mouse. Lines indicate the average value. () 44 expression by splenic T cells. (Left) Representative histograms showing 44 expression. Numbers indicate %44 high cells. lack line, 44; gray-filled line, isotype control. (Right) Percentage of T cells with 44 high phenotype in untreated mice or upon transient and sustained treatments (n = ). () xpression of activation markers on T cells from spleen. (Left) Representative histograms showing 69, P1, and KLRG1 expression on T cells. Numbers indicate percentage. (Right) Percentage of 69 + (n = 3), P1 + (n = ), and KLRG1 + (n = 3) T cells in spleens of untreated mice or upon transient and sustained treatments. () Percentage (Left) and MI (Right) of INγ + T cells upon PM/ionomycin stimulation. (n = 21), transient (n = 21), sustained (n = 2). ach circle represents an individual mouse. Lines indicate the average value. () INγ production by and degranulation of T cells stimulated on anti-3ε/2 coated plates in the presence of anti-17a-p or isotype control (not shown) antibody. Percentage of 17a + INγ (black) and INγ + (white) T cells from untreated mice (n = 6) or upon transient (n =7) and sustained (n = 6) treatments shown. () Transferred 4.1 + OTI T cells were stimulated with SIINKL peptide and percentage of INγ + OTI cells was determined (n = 3). Significance: P <., P <.1, P <.1; NS, not significant. ata are means ± S. IL-/IL-Rα NK cells T cells Mouse IL- + Murine IL-Rα 2 16 12 1 %INγ+ cells 1 6 4 2 Human IL- + Murine IL-Rα 16 12 4 %INγ+ cells 1 6 4 2 ig. S6. omparison of the effect of mouse and human IL- in IL-/IL-Rα complexes on INγ production by NK and T cells. IL-/IL-Rα complexes were prepared using mouse (2 μg) or human (. μg) IL- with murine IL-Rα (12 μg and 3 μg, respectively). Representative bar graphs showing INγ production by NK and T cells in untreated mice or upon transient or sustained treatments (n = 3). Significance: P <., P <.1, P <.1; NS, not significant. ata are means ± S. lpek et al. www.pnas.org/cgi/content/short/1121217 4of

Table S1. Lowered activation status and altered balance of activating and inhibitory receptors on NK cells upon sustained in vivo stimulation with IL-/IL-Rα complexes Marker Parameter analyzed (% or MI) Sample size 22 % 6 3.6 ± 6.1 9.9 ± 2.1 3.4 ± 11. 11c MI 6 2. ± 4.7 93.7 ±.3 49.2 ± 13.7 44 MI 4 424. ± 97.2 672.3 ± 14.2 314. ±.2 43 MI 4 7.9 ± 243. 1414. ± 7.2 7. ± 39. 69 % 6 19. ± 3.7 46. ±. 49.3 ± 6.1 NKG2 MI 22. ± 1. 3.4 ± 2.6 26.4 ± 6.2 NKp46 MI 3 16 ±. 22.7 ± 3. 162. ±. 24 MI 7.4 ± 19.2.6 ± 19.2 17. ± 1 4 MI 3 29.4 ±.4 3.7 ± 1.2 26. ±.6 NM1 % 6 69.4 ± 2. 74. ± 1.. ± 2.9 Ly-49H % 6.6 ±.1 4. ± 2.2 3.7 ±.6 Ly-49 % 3 49.7 ±. 43.4 ± 1. 2.3 ± 2. NKG2 % 6 49.7 ±.9 66.7 ± 3.2 77.1 ± 1. Ly-49I// % 3 3.6 ± 3. 43.9 ± 2. 4.3 ± 1. MI, mean fluorescence intensity. lpek et al. www.pnas.org/cgi/content/short/1121217 of

2024 © healthdocbox.com Privacy Policy | Terms of Service | Feedback